# Washington University School of Medicine: Phase 2 study in Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) (40 participants)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Washington University School of Medicine |
| Sponsor type | Academic and hospital |
| Study | Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma |
| NCT ID | NCT07901803 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | Head and Neck (HNSCC); Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M); Head and Neck Squamous Cell Carcinoma; Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma |
| Intervention types | drug |
| Target enrollment | 40 |
| Site countries | United States |
| Posted | 2026-10-28 |
| Planned start | 2026-12-31 |
| Event | Newly registered study |
| Event date | 2026-10-28 |

## Why this score
- Posted in the last two weeks.
- Phase 2: multi-site, larger budget.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07901803). Last refreshed: 2026-11-06T09:49:51.899Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.